Introduction
Multiple myeloma (MM) is a hematologic malignancy characterized by a pattern of remission and inevitable relapse. While induction therapy and autologous stem cell transplantation (ASCT) have significantly improved initial outcomes, maintenance therapy—long-term, low-dose treatment following consolidation—is now a standard of care to deepen clinical response and delay disease progression.
However, clinical uncertainty remains regarding the optimal drug class for maintenance. The two primary options are Proteasome Inhibitors (PIs), such as bortezomib, and Immunomodulators (IMiDs), such as thalidomide or lenalidomide. Additionally, the ideal duration of maintenance therapy remains a subject of debate, balancing long-term efficacy against cumulative toxicity. This study provides real-world evidence from a 7-year Chinese cohort to address these critical clinical questions.
Methods
This retrospective study analyzed 226 patients with newly diagnosed multiple myeloma (NDMM) treated at the First Affiliated Hospital of Zhejiang University between 2013 and 2018. Patients were stratified by disease stage using the International Staging System (ISS), Revised ISS (R-ISS), and Durie-Salmon (DS) criteria.
The cohort was divided into those receiving maintenance therapy (n=181) and those who did not (n=45). Within the maintenance group, 127 patients received PI-based regimens (primarily bortezomib) and 54 received IMiDs. Survival outcomes, including Progression-Free Survival (PFS) and Overall Survival (OS), were analyzed using Kaplan-Meier curves. The study also evaluated the impact of maintenance duration, comparing outcomes for treatment periods of <12 months, 12–24 months, and >24 months.
Results
Survival Outcomes and Comparative Efficacy
Maintenance therapy significantly improved survival across the cohort. The median PFS for the maintenance group was 41.1 months compared to 10.5 months for the no-maintenance group (p < 0.001). Median OS was not reached in the maintenance group, while it was 38.6 months in the control group (p < 0.001).
When comparing drug classes, bortezomib-based maintenance demonstrated a clear advantage over IMiDs. The median PFS was 43.7 months for the PI group versus 38.5 months for the IMiD group (p = 0.034). Similarly, OS was significantly improved with PI maintenance (median not reached vs. 78.5 months, p = 0.041).
Response Upgrading and Subgroup Benefits
Maintenance therapy did more than just sustain remission; it actively deepened the clinical response. Patients receiving maintenance were significantly more likely to "upgrade" their response (e.g., from Partial Response to Very Good Partial Response or better) compared to the control group (34.3% vs. 13.3%, p = 0.006).
Subgroup analysis revealed that the benefits of bortezomib-based maintenance were most pronounced in high-risk patients (ISS 2-3 and R-ISS 2-3) and younger patients (<65 years). For high-risk patients in ISS stages 2-3, PI maintenance achieved a 3-year PFS of 57.0%, compared to 40.3% for those on IMiDs.
Optimal Duration of Therapy
The study identified a "sweet spot" for treatment duration. While receiving maintenance for at least 12 months dramatically improved survival compared to shorter durations (5-year OS of 91.9% vs. 51.1%), there was no statistically significant difference in survival between patients treated for 12–24 months and those treated for more than 24 months (p = 0.292).
Discussion and Conclusion
This real-world study confirms that maintenance therapy is essential for improving survival in NDMM. Bortezomib-based regimens appear superior to IMiDs, particularly for high-risk and younger patient populations. Furthermore, the data suggests that a maintenance duration of 12 to 24 months may provide a satisfactory balance between efficacy and treatment burden.
Limitations of the study include its retrospective nature and the relatively small size of the IMiD and control subgroups. Future research should explore the role of newer oral PIs, such as ixazomib, which may offer similar survival benefits with improved patient compliance and reduced toxicity. Additionally, the integration of Minimal Residual Disease (MRD) monitoring will be crucial for personalizing the duration of maintenance therapy in the future.
Summary updated